Tagrisso 80 mg tablets | Osimertinib 80 mg Apple Pharmaceuticals
Tagrisso 80 mg tablets | Osimertinib 80 mg Apple Pharmaceuticals
Tagrisso tablet 80 mg ( osimertinib )
Tagrisso 80mg tabletcontaining the active substance,known as Osimeritinib, which was previously known as Mereletinib.
Tagrisso 80 mg is considered a third-generation drug that is available in tablet form.
Tagrisso 80 mg tablet is an inevitable, selectively rejected epidermal growth factor receptor inhibitor containing an anti-cancer effect.
Pharmacological category Tagrisso 40mgis tyrosine kinase inhibitor.
Tagrisso 80 mg is considered a third-generation drug that is available in tablet form.
Tagrisso 80 mg tablet is an inevitable, selectively rejected epidermal growth factor receptor inhibitor containing an anti-cancer effect.
Pharmacological category Tagrisso 40mgis tyrosine kinase inhibitor.
INDICATIONS
Tagrisso 80mg ( osimertinib ) The tablet is widely indicated as a first-line therapy for advanced non-small cell lung cancer with an EGFR mutation -positive patient.
Tagrisso 80 mg is also used to treat patients with progressive EGFR T792M, positive for NSCLC mutations, the disease has progressed to or after treatment with a tyrosine kinase inhibitor.
Tagrisso 80 mg is also used to treat patients with progressive EGFR T792M, positive for NSCLC mutations, the disease has progressed to or after treatment with a tyrosine kinase inhibitor.
DOSAGE
The usual prescribed doses of tablets Tagrisso: 80 mg tablets should be taken as a single dose.
Tagrisso 80 mg tablets should be administered with or without food.
If a patient has difficulty swallowing Tagrisso 80 mg tablets per se, they should disperse the tablet in 60 ml of non-carbonated water and drink the solution immediately.
Do not break, crush or chew a Tagrisso tablet .
Discontinue therapy in conditions such as:
Interstitial lung disease
QT extension
Symptomatic congestive heart failure
In pain management
Degree III or severe: kept tablet Tagrisso 80 mg for 3 weeks
Degree from 0 to II: follow in a dose of 80 mg or 40 mg as a single dose.
If after 3 weeks of development is not observed: discontinue therapy.
With the simultaneous appointment of Tagrisso 80 mg with inducers of CYP3A4, the dose of Tagrisso 80 mg should be increased to 160 mg as a single dose and then 80 mg within 3 weeks after the cancellation of strong inducers of CYP3A4.
Tagrisso 80 mg tablets should be administered with or without food.
If a patient has difficulty swallowing Tagrisso 80 mg tablets per se, they should disperse the tablet in 60 ml of non-carbonated water and drink the solution immediately.
Do not break, crush or chew a Tagrisso tablet .
Discontinue therapy in conditions such as:
Interstitial lung disease
QT extension
Symptomatic congestive heart failure
In pain management
Degree III or severe: kept tablet Tagrisso 80 mg for 3 weeks
Degree from 0 to II: follow in a dose of 80 mg or 40 mg as a single dose.
If after 3 weeks of development is not observed: discontinue therapy.
With the simultaneous appointment of Tagrisso 80 mg with inducers of CYP3A4, the dose of Tagrisso 80 mg should be increased to 160 mg as a single dose and then 80 mg within 3 weeks after the cancellation of strong inducers of CYP3A4.
one
Absorption:
The peak time of plasma concentration of osimertinib reaches within 6 hours
Distribution: Volume Distribution 918L
Plasma protein bound to Osimeritinib is 95%
Metabolism:
Osimeritinib metabolism occurs through oxidation. The two pharmacologically active metabolites of Osimeritinib are AZ7550 and AZ5104
Excretion: average end half-life of 48 hours. The clearance value of 14.3 l / h. 68% metabolite excreted in the feces; 14% through the urine excreted 2% of the unchanged form of the drug
The peak time of plasma concentration of osimertinib reaches within 6 hours
Distribution: Volume Distribution 918L
Plasma protein bound to Osimeritinib is 95%
Metabolism:
Osimeritinib metabolism occurs through oxidation. The two pharmacologically active metabolites of Osimeritinib are AZ7550 and AZ5104
Excretion: average end half-life of 48 hours. The clearance value of 14.3 l / h. 68% metabolite excreted in the feces; 14% through the urine excreted 2% of the unchanged form of the drug
MECHANISM
Osimeritinib has a similar effect compared with other tyrosine kinase inhibiting drugs.
Osimeritinib 80mg named tyrosine epidermal kinase development factor receptor inhibitor, which is available on the surface of tumor cells.
Osimeritinib does not reversibly converge with the EGFR mutant type in 9 folds than the wild genus.
Prohibits EGFR sharpening changes exon 19 Del and L858R
prompts transformed unformed in a pattern.
Finally, overthrow the action against wild EGFR
Osimeritinib 80mg named tyrosine epidermal kinase development factor receptor inhibitor, which is available on the surface of tumor cells.
Osimeritinib does not reversibly converge with the EGFR mutant type in 9 folds than the wild genus.
Prohibits EGFR sharpening changes exon 19 Del and L858R
prompts transformed unformed in a pattern.
Finally, overthrow the action against wild EGFR
PRECAUTIONS
Some of the side effects occur during therapy:
Interstitial lung disease: to avoid this problem, refrain or stop taking pills Tagrisso 80 mg .
Expansion of QTc: Avoid concurrent use Tagrisso 80mg with the drug to prolong the QTc
Cardiomyopathy: periodic heart monitoring is performed; in this state, discontinue therapy.
Keratitis: frequent monitoring of keratitis and support measures
Embryo fetal toxicity: Tagrisso 80mg tablet used in pregnancy period causes fetal damage.
Interstitial lung disease: to avoid this problem, refrain or stop taking pills Tagrisso 80 mg .
Expansion of QTc: Avoid concurrent use Tagrisso 80mg with the drug to prolong the QTc
Cardiomyopathy: periodic heart monitoring is performed; in this state, discontinue therapy.
Keratitis: frequent monitoring of keratitis and support measures
Embryo fetal toxicity: Tagrisso 80mg tablet used in pregnancy period causes fetal damage.
DRUG INTERACTION
Tagrisso 80mg tablet combines with strong CYP3A4 inducers causes reducing the exposure of Osimeritinib, this may leads to reduce the efficacy of Tagrisso.
Avoid the concomitant use of strong CYP3A4 inducers with Tagrisso 80mg tablets.
Tagrisso 80mg tablet combined with BCRP substrates may causes increasing the exposure of BCRP substrates. Thus results as increasing the adverse effects related to BCRP substrates
Avoid concomitant use of Tagrisso 80mg tablet with drug which induce the QT prolongation. In this case patients should be undergone periodic ECG monitoring.
Avoid the concomitant use of strong CYP3A4 inducers with Tagrisso 80mg tablets.
Tagrisso 80mg tablet combined with BCRP substrates may causes increasing the exposure of BCRP substrates. Thus results as increasing the adverse effects related to BCRP substrates
Avoid concomitant use of Tagrisso 80mg tablet with drug which induce the QT prolongation. In this case patients should be undergone periodic ECG monitoring.
CONTRAINDICATION
No contraindication occurred during the therapy
In some patient’s anaphylactic reaction may occur due to patients may contraindicated to the ingredient of the product
In some patient’s anaphylactic reaction may occur due to patients may contraindicated to the ingredient of the product
MISSED DOSE
Tagrisso 80 mg is a chemotherapeutic drug, in the case of a missed dose, skip the missed dose and follow the usual dosing regimen.
SIDE EFFECTS
Common side effects:
Fatigue; Lymphocytopenia (low white blood cell count); Low sodium content; Confused breathing; Musculoskeletal pain; Decreased appetite; Cough
Less common side effects:
Constipation; Elevated serum creatinine; Colitis; Low potassium; Low in magnesium; High calcium content; Vomiting; Weakness; Diarrhea; High potassium; Low calcium content; Edema; Fever; Rash; Abdominal pain; Elevated serum AST; thrombocytopenia; Increased serum alkaline phosphatase; Chest pain; Weight loss. These are side effects .
Fatigue; Lymphocytopenia (low white blood cell count); Low sodium content; Confused breathing; Musculoskeletal pain; Decreased appetite; Cough
Less common side effects:
Constipation; Elevated serum creatinine; Colitis; Low potassium; Low in magnesium; High calcium content; Vomiting; Weakness; Diarrhea; High potassium; Low calcium content; Edema; Fever; Rash; Abdominal pain; Elevated serum AST; thrombocytopenia; Increased serum alkaline phosphatase; Chest pain; Weight loss. These are side effects .
Comments
Post a Comment